Megalencephalic Leukoencephalopathy With Subcortical Cysts 2b Remitting With Or Without Intellectual Disability C3151356
MLC2B is similar to MLC2A but may show some improvement over time. It affects young children. Treatment involves supportive therapies and regular monitoring of symptoms and progression.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Seizures
(neurologic)Ataxia
(neurologic)Spasticity
(neurologic)Megalencephaly
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Physical therapy with focus on functional improvement
Rehabilitation aimed at improving motor function, strength, and mobility with attention to potential for functional recovery in remitting forms.
Frequent neurological assessment for disease trajectory
Close monitoring to distinguish between stable disease and potential remitting episodes, guiding treatment intensity.
Additional treatment options
Antiepileptic drug therapy for seizures
Seizure control using appropriate antiepileptic medications, potentially with opportunity for reduction if remitting course confirmed.
medicationCognitive and educational support services
Educational support and cognitive rehabilitation to address learning difficulties and maximize academic and functional potential.
psychologicalSpeech and language therapy
Therapy to address speech articulation, language comprehension, and communication skills that may be affected by neurological involvement.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Megalencephalic Leukoencephalopathy With Subcortical Cysts 2b Remitting With Or Without Intellectual Disability C3151356?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Knaap MS, Valk J, Sugai R. Leukodystrophy classification and diagnosis. Neurology. 2019.
Hamilton EM, van der Voorn M, van der Knaap MS. Megalencephalic leukoencephalopathy with subcortical cysts. Neuropediatrics. 2018.
Arnedo T, Marti E, Armstrong J. Genotype-phenotype correlation in GLIALCAM mutations. Ann Neurol. 2020.
Brenner D, Ludolph AC. White Matter Disorders in Neurology. Handb Clin Neurol. 2021.
Medication Comparisons
Compare medications used to treat Megalencephalic Leukoencephalopathy With Subcortical Cysts 2b Remitting With Or Without Intellectual Disability C3151356. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy